News stories about Thoratec (NASDAQ:THOR) have trended somewhat negative on Thursday, according to Accern Sentiment. The research firm identifies positive and negative media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Thoratec earned a coverage optimism score of -0.19 on Accern’s scale. Accern also gave press coverage about the medical instruments supplier an impact score of 45.9938555066759 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Shares of Thoratec (THOR) remained flat at $63.50 during trading on Thursday. Thoratec has a one year low of $25.04 and a one year high of $63.51. The company has a 50 day moving average price of $63.03 and a 200 day moving average price of $51.62.
Thoratec Company Profile
Thoratec Corporation develops, manufactures and markets medical devices used for mechanical circulatory support for the treatment of heart failure patients. The Company’s products include ventricular assist devices (VADs), such as HeartMate II Left Ventricular Assist System (HeartMate II), HeartMate III Left Ventricular Assist System, Thoratec Paracorporeal Ventricular Assist Device (PVAD) and Thoratec Implantable Ventricular Assist Device (IVAD).
Receive News & Ratings for Thoratec Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thoratec Co. and related companies with MarketBeat.com's FREE daily email newsletter.